Introduction: Efficacy of renin-angiotensin-aldosterone system (RAAS) blockade using angiotensin-converting enzyme inhibitors (ACEi) in dogs with preclinical myxomatous mitral valve disease (MMVD) is controversial. Hypothesis: Administration of spironolactone (2–4 mg q 24 h) and benazepril (0.25–0.5 mg q 24 h) in dogs with preclinical MMVD, not receiving any other cardiac medications, delays the onset of heart failure (HF) and cardiac-related death. Moreover, it reduces the progression of the disease as indicated by echocardiographic parameters and level of cardiac biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI). Animals: 184 dogs with pre-clinical MMVD and left atrium-to-aortic root ratio (LA:Ao) ≥1.6 and normalized left ventricular end-diastolic diameter (LVEDDn) ≥1.7. Methods: This is a prospective, randomized, multicenter, single-blinded, placebo-controlled study. Primary outcome variable was time-to-onset of first occurrence of HF or cardiac death. Secondary end points included effect of treatment on progression of the disease based on echocardiographic and radiographic parameters, as well as variations of NT-proBNP and cTnI concentrations. Results: The median time to primary end point was 902 days (95% confidence interval (CI) 682-not available) for the treatment group and 1139 days (95% CI 732-NA) for the control group (p = 0.45). Vertebral heart score (p = 0.05), LA:Ao (p < 0.001), LVEDDn (p < 0.001), trans-mitral E peak velocity (p = 0.011), and NT-proBNP (p = 0.037) were lower at the end of study in the treatment group. Conclusions: This study failed in demonstrating that combined administration of spironolactone and benazepril delays onset of HF in dogs with preclinical MMVD. However, such treatment induces beneficial effects on cardiac remodeling and these results could be of clinical relevance.

DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study / Borgarelli, M.; Ferasin, L.; Lamb, K.; Bussadori, C.; Chiavegato, D.; D'Agnolo, G.; Migliorini, F.; Poggi, M.; Santilli, R. A.; Guillot, E.; Garelli-Paar, C.; Toschi Corneliani, R.; Farina, F.; Zani, A.; Dirven, M.; Smets, P.; Guglielmini, C.; Oliveira, P.; Di Marcello, M.; Porciello, F.; Crosara, S.; Ciaramella, P.; Piantedosi, D.; Smith, S.; Vannini, S.; Dall'Aglio, E.; Savarino, P.; Quintavalla, C.; Patteson, M.; Silva, J.; Locatelli, C.; Baron Toaldo, M.. - In: JOURNAL OF VETERINARY CARDIOLOGY. - ISSN 1760-2734. - 27:(2020), pp. 34-53. [10.1016/j.jvc.2019.12.002]

DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study

Crosara S.;Quintavalla C.;
2020

Abstract

Introduction: Efficacy of renin-angiotensin-aldosterone system (RAAS) blockade using angiotensin-converting enzyme inhibitors (ACEi) in dogs with preclinical myxomatous mitral valve disease (MMVD) is controversial. Hypothesis: Administration of spironolactone (2–4 mg q 24 h) and benazepril (0.25–0.5 mg q 24 h) in dogs with preclinical MMVD, not receiving any other cardiac medications, delays the onset of heart failure (HF) and cardiac-related death. Moreover, it reduces the progression of the disease as indicated by echocardiographic parameters and level of cardiac biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI). Animals: 184 dogs with pre-clinical MMVD and left atrium-to-aortic root ratio (LA:Ao) ≥1.6 and normalized left ventricular end-diastolic diameter (LVEDDn) ≥1.7. Methods: This is a prospective, randomized, multicenter, single-blinded, placebo-controlled study. Primary outcome variable was time-to-onset of first occurrence of HF or cardiac death. Secondary end points included effect of treatment on progression of the disease based on echocardiographic and radiographic parameters, as well as variations of NT-proBNP and cTnI concentrations. Results: The median time to primary end point was 902 days (95% confidence interval (CI) 682-not available) for the treatment group and 1139 days (95% CI 732-NA) for the control group (p = 0.45). Vertebral heart score (p = 0.05), LA:Ao (p < 0.001), LVEDDn (p < 0.001), trans-mitral E peak velocity (p = 0.011), and NT-proBNP (p = 0.037) were lower at the end of study in the treatment group. Conclusions: This study failed in demonstrating that combined administration of spironolactone and benazepril delays onset of HF in dogs with preclinical MMVD. However, such treatment induces beneficial effects on cardiac remodeling and these results could be of clinical relevance.
DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study / Borgarelli, M.; Ferasin, L.; Lamb, K.; Bussadori, C.; Chiavegato, D.; D'Agnolo, G.; Migliorini, F.; Poggi, M.; Santilli, R. A.; Guillot, E.; Garelli-Paar, C.; Toschi Corneliani, R.; Farina, F.; Zani, A.; Dirven, M.; Smets, P.; Guglielmini, C.; Oliveira, P.; Di Marcello, M.; Porciello, F.; Crosara, S.; Ciaramella, P.; Piantedosi, D.; Smith, S.; Vannini, S.; Dall'Aglio, E.; Savarino, P.; Quintavalla, C.; Patteson, M.; Silva, J.; Locatelli, C.; Baron Toaldo, M.. - In: JOURNAL OF VETERINARY CARDIOLOGY. - ISSN 1760-2734. - 27:(2020), pp. 34-53. [10.1016/j.jvc.2019.12.002]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1760273419301560-main.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2872034
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? ND
social impact